Boehringer Ingelheim signs Option to Acquire Trutino Biosciences
14.6.2022 19:00:00 EEST | Business Wire | Press release
Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech company.
Trutino Biosciences is a pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Boehringer Ingelheim is dedicated to a two-pronged research strategy to fight cancers: through cancer cell-directed and immune cell-targeting compounds. The ongoing research partnership between Boehringer Ingelheim and Trutino is part of an overarching effort to mobilize a patient’s immune system to fight cancer.
“Boehringer Ingelheim is excited to extend our partnership with Dr. Kim and his outstanding team at Trutino Biosciences. Our existing collaboration has made rapid and impressive progress in a short time frame, and we expect this field to have potential combination benefits with our existing immune-targeting assets,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research, Boehringer Ingelheim. “The selective activation of specific cytokines localized in the tumor microenvironment holds enormous promise and has the potential to be a key element in fully harnessing the power of the immune system to fight cancer.”
“It's been two years since our initial strategic alliance began and we are very excited to further strengthen our partnership with Boehringer Ingelheim, a leader in cancer immunology, to advance potential cytokine therapeutic options that will transform the lives of cancer patients worldwide,” said Phillip Kim, Ph.D., MBA, Founder and CEO of Trutino Biosciences. “Boehringer Ingelheim has a deep commitment to our innovative scientific approaches and to bringing novel cancer therapies to patients. This global partnership validates the broad potential of our proprietary ‘On Demand Cytokine’ platform. As part of this expanded collaborative framework, we aim to rapidly develop a new generation of cytokine therapies as single agent and in combination with Boehringer Ingelheim's pipeline portfolio of cancer vaccines, oncolytic viruses, T cell engagers and other therapeutic modalities."
Under the agreement, Boehringer Ingelheim reserves the right to purchase all shares of Trutino Biosciences once specified program milestones have been achieved within a given timeframe. Until that time, Trutino will continue to operate as an independent company, with the existing fruitful strategic partnership and collaboration agreement between the companies continuing uninterrupted.
The transaction consideration consists of an option fee, the issuance of a convertible note and fixed purchase price terms to acquire Trutino Biosciences once pre-defined milestones are achieved. The option fee and principal amount of the convertible note funded by Boehringer Ingelheim at the signing of the option will collectively fully finance Trutino Biosciences through the next major development milestones of Trutino Biosciences.
Boehringer Ingelheim and Trutino Biosciences were introduced in 2019 during one of Boehringer Ingelheim’s “Grass Roots Innovation” events in San Diego. From there, in 2020 the companies forged a multi-target strategic partnership on conditionally masked cytokines. Boehringer Ingelheim’s Grass Roots programs provide biotech entrepreneurs mentoring and access to expertise and possible funding. To learn more, visit Grass Roots Innovation.
Please click on the link for "Notes to Editors":
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005761/en/
Contact information
Media Contacts
Boehringer Ingelheim
Reinhard Malin (CET time zone)
Innovation Unit/Bio Comms, Corp. Affairs
P: 49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com
Linda Ruckel (EST time zone)
Innovation Unit/Bio Comms, Corp. Affairs
P: 1 203-791-6672
linda.ruckel@boehringer-ingelheim.com
Trutino Biosciences
Phillip Kim
+1 858-880-5501
pkim@trutinobio.com
John Zacamy
+1 212-486-2760
info@trutinobio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Measuring Muscles with Quantitative MRI: New Study Published in Neurology Expands the Evidence for Using MRI Biomarkers in SBMA26.8.2026 15:27:00 EEST | Press release
AMRA Medical is pleased to announce the publication of new research in Neurology demonstrating the potential of quantitative whole-body MRI to measure disease progression in Spinal and Bulbar Muscular Atrophy (SBMA), a rare, progressive neuromuscular disease. The research was also selected for the cover of the issue, providing additional visibility for this important work in neuromuscular disease research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826386576/en/ AMRA Medical - Measuring Muscles with Quantitative MRI The manuscript, titled “Muscle MRI as an imaging biomarker of muscle damage in patients with spinal and bulbar muscular atrophy” highlights how MRI-based muscle composition biomarkers can provide sensitive and objective measures of disease-related change over time. With AMRAⓇ Researcher, the study evaluated 25 participants with SBMA to investigate the ability of fat-referenced MRI to assess changes in musc
KEWPIE IT. London discovers the Mayo behind the Iconic Tamago Sando26.8.2026 15:10:00 EEST | Press release
Kewpie Corporation(TOKYO:2809) is inviting Londoners to discover how one simple squeeze can transform one of the world's most iconic sandwiches. Through a new experiential pop-up in Covent Garden Piazza, the iconic Japanese mayonnaise brand is bringing its rich, creamy, umami flavour to the heart of London's food scene, celebrating the ingredient that elevates the Tamago Sando AKAthe iconic Japanese Egg Sandwich. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826081552/en/ An image of the pop-up scheduled to take place at Covent Garden Piazza in London KEWPIE MAYONNAISE is mostly made with egg yolks (not whole eggs), which is responsible for its richness and umami flavour, alongside their proprietary vinegars. With its signature bottle and unique taste, KEWPIE MAYONNAISE has earned a loyal following among chefs and food lovers for its distinctive richness and depth of flavour. Rather than following food trends, the brand
Copeland Appoints Sandro Matic as President, Americas, and Gwen Cheramy as President, Europe26.8.2026 15:00:00 EEST | Press release
Copeland, a global provider of compression technologies and controls solutions, today announced that Gwen Cheramy will join the company as President of its Europe business on Oct. 1, 2026, and that Sandro Matic will assume the role of President of its Americas business on Sept. 1, 2026. Matic will continue to lead Europe on an interim basis until Cheramy joins Copeland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826567313/en/ Sandro Matic, President, Americas for Copeland "Sandro and Gwen are both proven leaders with strong track records of delivering results within our industry,” said Ross B. Shuster, CEO of Copeland. "In their new roles, they will be instrumental in providing leadership to our local colleagues, supporting our customers, and advancing Copeland’s strategic priorities across their respective regions while helping execute our global strategy.” Matic joined the business in 2011, initially with Emerson, a
NetApp Named a Leader in the 2026 Gartner® Magic Quadrant™ for Enterprise Storage Platforms26.8.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2026 Gartner Magic Quadrant for Enterprise Storage Platforms, continuing to acknowledge NetApp as a Leader in this market from its inaugural edition of this report in 2025. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. Additionally, the 2026 Gartner Critical Capabilities for Enterprise Storage Platforms report ranks NetApp first in the Hybrid Cloud Storage Use Case and second in the Hybrid Platform Services Use Case. NetApp believes this recognition validates the company’s ability to help customers address their most pressing data challenges while offering more predictable hardware delivery timelines than its competitors. The NetApp Platform is an intelligent, governed foundation that provides zero-copy access to an organization’s data, wherever it resides. It enables
Pure Lithium Announces Unprecedented Cycling Results From Its Advanced Anode™ Lithium Metal Battery Technology26.8.2026 14:00:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, today announced that our Advanced Anode™ battery, technology developed specifically to enable ultra-long cycling, has achieved more than 9,315 cycles. The cells continue to cycle in the Company's laboratory. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826201214/en/ To the Company’s knowledge, no other lithium metal battery in development has achieved such results under equivalent testing conditions. The performance of the Company’s battery, achieved with negligible capacity fade, far exceeds today’s commercial lithium-ion battery cycling requirements across numerous applications, where performance typically ranges from 250 to 2,000 cycles, depending on the application. These results were achieved at 100% depth of discharge, and charge rates of 1C: 1C.1 “The results of Pure Lithium’s cycling performance are disruptive. Cycle life
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom